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Five papers are submitted to support an application for the award of PhD by published 
work. These papers describe work carried out over a six-year period at the University of 
Bristol. The focus of all of the publications is the investigation of clinical pain mechanisms 
and strategies for its management in dogs and, to a lesser extent, cats in the United 
Kingdom. The publications employ a range of methodological approaches, as appropriate to 
the research question; and considered as a whole they examine clinical pain topics ranging 
from acute to persistent forms of pain, and from individual to population level.  
On admission to the Royal College of Veterinary Surgeons, members promise and solemnly 
declare that “my constant endeavour will be to ensure the health and welfare of animals 
committed to my care”1. However, historically acute perioperative pain has been 
undertreated by Veterinary Surgeons in a number of countries, including the UK. Persistent 
(“chronic”) pain in humans currently represents the one of the greatest healthcare burdens 
and significantly decreases quality of life in affected people yet is often poorly responsive to 
common analgesic interventions. Similarly, painful conditions such as osteoarthritis which 
cause persistent pain in people are common in dogs and cats and have been identified as 
one of the top three welfare issues in pet dogs. Robust examination of pain and analgesic 
strategies intended to manage pain in animals, and communication of the resulting findings 
                                                        
1 https://www.rcvs.org.uk/setting-standards/advice-and-guidance/code-of-professional-conduct-for-
veterinary-surgeons/ accessed 4th July 2018 
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to an appropriate audience therefore have the potential to improve welfare for a significant 
number of animals undergoing veterinary treatment; and this consideration has motivated 
the research presented within this work. 
Paper 1 reports a evaluation of the analgesic efficacy of two opioid drugs with marketing 
authorisation for use in dogs in a highly clinically relevant model of orthopaedic surgery, 
within a standardised and pertinent anaesthetic management protocol. This research has 
contributed to an evidence base enabling, for example, the recommendation of full µ 
agonist opioids in preference to partial agonists for major surgery in dogs (Murrell, 2014), 
which would be expected to improve the provision of perioperative analgesia and animal 
welfare.  
Paper 2 details a cross-sectional survey of perioperative analgesic prescribing practices 
amongst UK veterinary surgeons and draws comparisons with previous surveys. The results 
indicate significant improvement in the use of perioperative opioid and non-steroidal anti-
inflammatory drugs for management of perioperative pain, and highlights areas such as 
local analgesia and postoperative administration of non-steroidal anti-inflammatory drugs 
to cats where prescribing could be improved.  
Paper 3 considers the adverse events associated with administration of analgesics, 
specifically non-steroidal anti-inflammatory drugs. A number of challenges were 
encountered in accessing and interpreting the data which are discussed, however the work 
documents the state of our knowledge in respect of adverse event reporting in dogs and 
cats, and presents opportunities for further investigations.  
Papers 4 and 5 resulted from a 3 year experimental investigation into changes in spinal cord 
processing of nociceptive stimuli in client owned dogs with osteoarthritis. Paper 4 details 




processing under general anaesthesia – a prerequisite for humane data collection in client 
owned animals. Electromyographic responses to nociceptive stimuli are recorded as a 
quantifiable estimation of spinal nociceptive processing. Paper 5 describes the application of 
the technique to a population of client owned animals diagnosed with pelvic limb 
osteoarthritis, and documents increases in nociceptive processing in affected animals, 
compared to a control group of unaffected client owned dogs. Additionally, in a subgroup of 
animals recruited, a technique for eliciting a form of endogenous analgesia (diffuse noxious 
inhibitory controls, DNIC) is described in dogs for the first time, and less effective DNIC is 
identified in animals affected by osteoarthritis. These results corroborate previously 
published evidence of widespread somatosensory sensitisation in dogs affected by 
osteoarthritis, and further identify that one mechanism which may contribute to 
sensitisation is a reduced efficiency of DNIC. These findings are consistent with 
investigations into people affected by osteoarthritis, and thus further validate canine 
osteoarthritis as a potential model for the human disease.  
Considered together these five papers represent a significant contribution to our 




Award of PhD by published work 
 
This manuscript and collection of papers is submitted by James Russell Hunt, who is applying 




Clinically relevant differences in efficacy between licensed doses of opioid analgesics in 
dogs undergoing orthopaedic surgery 
 
Paper 1 Hunt, J.R., Attenburrow, P.M., Slingsby, L.S., Murrell, J.C., 2013. Comparison of 
premedication with buprenorphine or methadone with meloxicam for postoperative 
analgesia in dogs undergoing orthopaedic surgery. Journal of Small Animal Practice 54, 418–
424. doi:10.1111/jsap.12103 
 
Nationwide survey demonstrating improvements in reported provision of perioperative 
analgesia by UK Veterinary Surgeons over the previous 15 years and highlighting potential 
for improved post-discharge analgesia prescription 
 
Paper 2 Hunt, J.R., Knowles, T.G., Lascelles, B.D.X., Murrell, J.C., 2015. Prescription of 
perioperative analgesics by UK small animal veterinary surgeons in 2013. Vet Rec 176, 493. 
doi:10.1136/vr.102834 
 
Interrogation of post-marketing authorisation adverse events reported to the UK 
Veterinary Medicines Regulator 
 
Paper 3  Hunt, J.R., Dean, R.S., Davis, G.N.D., Murrell, J.C., 2015. An analysis of the relative 
frequencies of reported adverse events associated with NSAID administration in dogs and cats 






Development of a suitable anaesthetic protocol to facilitate recording of nociceptive 
withdrawal reflexes in dogs and preliminary investigations into the evocation of descending 
nociceptive modulation 
 
Paper 4   Hunt, J., Murrell, J., Knazovicky, D., Harris, J., Kelly, S., Knowles, T.G., Lascelles, B.D.X., 
2016. Alfaxalone Anaesthesia Facilitates Electrophysiological Recordings of Nociceptive 
Withdrawal Reflexes in Dogs (Canis familiaris). PLoS ONE 11, e0158990. 
doi:10.1371/journal.pone.0158990 
 
Application of anaesthetic technique to investigate nociceptive withdrawal reflexes in dogs 
affected by osteoarthritis compared with unaffected animals and development of a 
paradigm to investigate diffuse noxious inhibitory control in anaesthetised dogs 
 
Paper 5   Hunt, J.R., Goff, M., Jenkins, H., Harris, J., Knowles, T.G., Lascelles, B.D.X., Enomoto, 
M., Mendl, M., Whay, H.R., Murrell, J.C., 2018. Electrophysiological characterisation of central 






The work which led to these publications was performed whilst undertaking research posts 
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1. An Introduction to Pain 
 
Pain is currently defined by the International Association for the Study of Pain (IASP) as “An 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage” (IASP, 2014). The notes accompanying the 
definition state “The inability to communicate verbally does not negate the possibility that 
an individual is experiencing pain and is in need of appropriate pain-relieving treatment.” 
(IASP, 2014). Cohen et al., (2018) have criticised the current definition on a number of 
grounds, including that; i. “unpleasant is an unsatisfactory descriptor”; ii. that the 
accompanying Note on Usage states, “Many people report pain in the absence of tissue 
damage or any likely pathophysiological cause; usually this happens for psychological 
reasons”, which they contend discriminates against pain conditions in which tissue damage 
or obvious pathophysiological cause is not readily identified; and iii. that the current 
definition “ascribes a singular phenomenology (unpleasant sensory and emotional 
experience) to all instances of pain”. These authors have proposed a changed definition of 
pain: “Pain is a mutually recognisable somatic experience that reflects a person’s 
apprehension of threat to their bodily or existential integrity” (Cohen et al., 2018). These 
criticisms of the current definition have been examined by Treede, (2018), who concluded 
that “the article by Cohen et al., (2018) will have done a great service to the field if we take it 
as an inspiration for broadening our approach to pain assessment, but not as a redefinition 
of pain.” 
Molony (1997) provided a working definition of animal pain as “an aversive sensory and 




integrity of its tissues; (note, there may not be any damage) it changes the animal's 
physiology and behaviour to reduce or avoid the damage, to reduce the likelihood of 
recurrence and to promote recovery; non-functional pain occurs when the intensity or 
duration of the experience is not appropriate for the damage sustained (especially if none 
exists) and when physiological and behavioural responses are unsuccessful in alleviating it”. 
In terms of evaluating the presence of clinical pain in mammals this definition serves us 
extremely well, and further work has developed measurement scales in order to estimate 
the degree of pain in different mammalian species in specific circumstances (e.g. Morton et 
al., 2005; Reid et al., 2017) . Contrary to this position, given that pain as defined by IASP 
comprises both a sensory and affective component, it has been argued that without insight 
into the conscious experiences of animals we cannot reliably predict that they may 
experience pain, and that we cannot infer its presence from analysis of behavioural 
responses to stimuli as “seemingly purposive behaviors in response to noxious stimuli are 
commonly expressed by decerebrate animals” (Rose et al., 2014). However, self-selection of 
analgesics in rats (Colpaert et al., 1980), domestic chickens (Danbury et al., 2000), and zebra 
fish (Sneddon, 2013) subject to inflammatory or nociceptive conditions strongly suggests 
some central integration of nociceptive stimuli resulting in behavioural choices to 
ameliorate the aversive condition, and may provide insight as to the animals’ subjective 
experience (Sneddon et al., 2014).  
 
Pain may have a number of origins, including nociceptive pain (“arising from actual or 
threatened damage to non-neural tissue and due to the activation of nociceptors”), 
nociplastic pain (“arising from altered nociception despite no clear evidence of actual or 
 17 
threatened tissue damage causing the activation of peripheral nociceptors or evidence for 
disease or lesion of the somatosensory system causing the pain”), and neuropathic pain 
(“pain caused by a lesion or disease of the somatosensory nervous system”) (IASP, 2014).  
Undoubtedly the ability to perceive, respond, and alter motivational state in the presence of 
noxious stimuli confers an evolutionary advantage, with evidence suggesting that such 
abilities are present in animals including hermit crabs, octopus, and numerous species of 
fish (Sneddon et al., 2014). For this reason nociceptive pain has been considered ‘adaptive’ 
(Becker et al., 2018), in contrast to ‘maladaptive’ nociplastic and neuropathic forms of pain. 
Despite potential evolutionary advantage, the presence of pain is expected to exert 
significant negative impacts on an individual’s quality of life (Wiseman-Orr et al., 2004; 
Botreau et al., 2007; Belshaw et al., 2015). Most ethical frameworks (Hernandez et al., 2018) 
would conclude that the relief of pain in their patients is an essential pursuit for veterinary 
surgeons. I have produced an example of an ethical matrix (Table 1) to summarise 
consequences of differing ethical approaches; the convergence of these ethical 
considerations strongly suggests that management of pain is ethically desirable. However, 
provision of suitable analgesia is predicated upon correct identification and assessment of 











Ethical framework Provision of analgesia Withholding of analgesia 
Deontological: “Ethical decisions are correct if they conform to a 
moral rule, law, or norm”. 
 
Mandated by RCVS code of conduct 
to ensure welfare – pain negatively 
affects welfare therefore should be 
managed. 
Would be acting against oath. Failure 
to prevent unnecessary suffering 
could lead to prosecution under the 
Animal Welfare Act, 2006. 
Utilitarianism: “greatest good (maximal pleasure, minimal 
suffering) for the greatest number of stakeholders”  
 
Relief of negative welfare 
associated with pain is likely to be 
considered a good outcome. In 
domesticated animals evolutionary 
advantages associated with pain 
are reduced/absent. 
Cost and side effects of analgesia may 
impact this assessment, but are more 
likely to indicate that an alternative 
analgesic strategy be considered 
rather than no analgesia provided.  
Virtue ethics: “Virtues are character traits that are reliably 
present in individuals. Examples include compassion, 
discernment, trustworthiness, integrity, conscientiousness, 
initiative, self-discipline, responsibility, integrity and 
accountability.” 
Compassion would promote the 
veterinary surgeon to take steps to 
alleviate pain. 
Failing to treat pain in a sentient 
animal would be unlikely to be 
considered virtuous. 
Contractarianism: “Ethical rules, norms and obligations derive 
from an explicit or implied contract or mutual agreement.” 
 
Animals are not considered able to 
consent to treatment or enter into 
contracts, this ethical approach 
may have limited utility in the 
question of analgesic provision.  
 
Ethics of care: “recognises our relationships and obligations of 
care that follow from these.” 
 
Analgesic provision is likely to be 
mandated by ethics of care. 
Failure to provide analgesia is likely to 
be considered a breach of the ethics 
of care. 
Table 1 Consideration of the ethical aspects of provision or withholding analgesia in domestic dogs and cats (after 





1.1 Adaptive Pain 
Although the current ISAP terminology does not define adaptive or maladaptive pain, acute 
pain is often considered to be an adaptive means of responding to potentially tissue 
damaging stimuli (Becker et al., 2018). As such, the components of adaptive pain comprise 
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nociceptive and inflammatory processes. Suprathreshold nociceptive stimulation provokes a 
reflex withdrawal reflex, increasing physical separation between the animal and the 
stimulus (Sherrington, 1910). Tissue damage causes the release and synthesis of signalling 
molecules (see peripheral sensitiation, below) which cause hyperalgesia and allodynia, 
manifesting in the behavioural consequences of protecting the injured site through 
alterations in posture or gait, and a reduction in movement based activities (Goldberg, 
2017). The experience of pain impacts learning and memory, with the adaptive outcome of 
reducing further exposure to potentially damaging stimuli (Gerber et al., 2014). In previous 
surveys of the UK veterinary profession, a degree of post-operative pain was considered 
beneficial by approximately one-third of veterinary surgeons in preventing overactivity post-
surgery (Capner et al., 1999). Recent guidelines for the delivery of anaesthesia to dogs and 




Nociception is defined as “The neural process of encoding noxious stimuli. Consequences of 
encoding may be autonomic (e.g. elevated blood pressure) or behavioural (motor 
withdrawal reflex or more complex nocifensive behaviour). Pain sensation is not necessarily 
implied” (IASP, 2014), whilst nociceptive pain is defined as “Pain that arises from actual or 
threatened damage to non-neural tissue and is due to the activation of nociceptors” (IASP, 
2014). Given the inability of veterinary patients to report their experiences, it has been 




cause pain in other mammals; “We can’t always know that our patient does hurt, but we can 
do our best to ensure that it doesn’t hurt” (Mathews et al., 2014). 
Nociception requires the transduction of physical stimuli (via thermo-, chemo-, or piezo- 
responsive ion channels, potentially acting in concert with specialised cutaneous schwann 
cells (Abdo et al., 2019), into alterations of membrane potential within nociceptor terminals 
of primary afferent fibres. The alterations in membrane potential may summate to generate 
action potentials that are transmitted via primary afferent A∂- and C- nerve fibres to the 
dorsal horn of the spinal cord or trigeminal ganglion where they synapse; primarily in 
laminae I, II, and V, with second order neurons (which may generate reflex motor 
responses) and interneuron circuits. These laminae were described initially in the spinal 
cord of the cat (Rexed, 1952) but a homologous arrangement has been reported in 
macaques (Ralston, 1979) and rats (Lorenzo et al., 2008), with comparative organisation 
identified in elasmobranch fish (Cameron et al., 1990). At the synapses between primary 
afferent nociceptive fibres and second order neurones, the nociceptive signal may be 
subject to modulation by both local and descending pathways before the final output is 
projected, via neurons in ascending tracts (most importantly the spinocervicothalamic in 
domestic carnivores, as opposed to the spinothalamic tract in man, and spinoparabrachial 
tract in rodents (Dostrovsky and Craig, 2013)) of the spinal cord, to areas of the brain which 
co-ordinate nocifensive responses and have the capacity to generate perception of the 
stimulus as painful (Bell, 2018). Given the well preserved organisation and pharmacology of 
the nervous system related to nociceptive processing, it is considered that nociceptive 
processing is comparable between mammalian species (Sneddon, 2018), but the non-linear 
association between nociception and pain, and the translational validity of laboratory pain 
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models to clinical pain states has been suggested as a limitation to the development of 
novel analgesics for clinical use in man or animals (Mao, 2012).   
 
1.3 Peripheral Sensitisation 
Tissue damage leading to cell disruption and peripheral immune cell activation releases 
chemical mediators which potentiate local pain via i) direct activation of nociceptors (e.g. 
bradykinin, 5-hydroxytryptamine (5-HT), adenosine tri-phosphate (ATP), tumour necrosis 
factor alpha (TNF-α), interleukin 1β (IL-1β) and ii) sensitisation (less negative resting 
membrane potential and recruitment of ‘silent’ (high threshold) nociceptors) (e.g. 
bradykinin, prostaglandin E2 (PGE2), 5-HT, protons (H+), TNF-α, IL-1β, nerve growth factor 
(NGF), histamine) (Woolf et al., 2004). These changes are described as ‘peripheral 
sensitisation’, and are experienced as primary hyperalgesia (“increased pain from a stimulus 
that normally provokes pain”), and allodynia, (“pain due to a stimulus that does not 
normally provoke pain”) (IASP, 2014). Peripheral sensitisation exhibits similar characteristics 
across mammalian species (e.g. Moncada et al., 1975;  Xu et al., 2000), and the success of 
non-steroidal anti-inflammatory drugs to manage pain and inflammation in a range of 
species likely follows from these conserved mechanisms (Lees et al., 2004) 
 
1.4 Central sensitisation 
Central sensitisation is defined as “Increased responsiveness of nociceptive neurons in the 
central nervous system to their normal or subthreshold afferent input” (Arendt-Nielsen et 




the receptive field of the neurons which innervate the site of injury), and potentially 
allodynia. Central sensitisation has been documented following ovariohysterectomy surgery 
in dogs (Lascelles et al., 1997), and in dogs with coxofemoral osteoarthritis (Tomas et al., 
2014). In man some biomarkers of central sensitisation are associated with reduced 
analgesic response to topical non-steroidal anti-inflammatory drug (NSAID) treatment 
(Edwards et al., 2016). Multiple mechanisms which may potentiate nociceptive signalling at 
the level of the spinal cord have been identified in experimental animal models and 
reviewed in detail (Sandkühler, 2009). These mechanisms include long term potentiation of 
nociceptive synapses, alterations in intrinsic plasticity, changes in inhibitory interneuron 
activity, altered balance between descending pro- and anti-nociceptive pathways, spreading 
of excitation from low threshold (Aβ) touch afferents to superficial (nociceptive related) 
synapses, and activation of microglia and astrocytes. Given that these examples of altered 
central nociceptive processing are associated with sensory phenomena of hyperalgesia and 
allodynia in animal models, it is believed that a number of these mechanisms are likely to be 
responsible for the development of hyperalgesia and allodynia in human clinical pain states 
(Jensen and Finnerup, 2014) and if this were to be the case, it would be reasonable to 
expect similar mechanisms to be responsible for central sensitisation in dogs and cats. 
Elucidating the relative contributions of differing mechanisms between different pain states 
and species would provide valuable insights as to potential targets for analgesics.     
High intensity nociceptive input at the dorsal horn has the potential to alter the processing 
of subsequent nociceptive signalling (long term potentiation, LTP) via changes to glutamate-
activated N-methyl-d-aspartate (NMDA) receptors, which result in loss of the magnesium 
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ion block of this ligand gated ion channel and augmented post-synaptic calcium ion influx in 
response to subsequent glutamate binding (Sandkühler, 2009).  
Intrinsic plasticity relates to neuronal membrane excitability, and determines how a given 
membrane depolarization translates into firing of action potentials. Specific factors 
governing this property are not currently well described, but increases in excitability 
associated with experimental activation of metabotropic glutamate receptors or 
antagonism of tonic inhibition via GABAB receptors have been reported (Derjean et al., 
2003). 
Around 30% of neurons in the spinal dorsal horn are inhibitory interneurons; activity in 
these cells prevents spontaneous discharges in dorsal horn cells, suppresses excitatory 
impulses, reduces spreading of excitation to somatotopically inappropriate regions, 
suppresses excitation of nociceptive specific dorsal horn cells by cross-talk from touch 
sensitive Aβ-fibres, and reduces pre-synaptic excitatory neurotransmitter release and post-
synaptic calcium dependent increases in membrane excitability (Sandkühler, 2009). 
Reduced activity in inhibitory interneurons may therefore contribute to perceptions of 
spontaneous pain, hyperalgesia, radiating pain, or allodynia.   
Microglia and astrocytes, non-neuronal cells within the central nervous system, may 
contribute to hyperalgesia and allodynia, and function to maintain a pro-nociceptive state. 
They may be activated by spinal dorsal horn mediators glutamate, ATP, prostaglandins, and 
bradykinin resulting from peripheral nerve damage or inflammation. Production of factors 
such as TNFα, IL-1β, PGE2 by non-neuronal cells can augment nociceptive synaptic function 
and membrane excitability (Milligan & Watkins, 2009). 
Descending serotonergic and noradrenergic pathways from midbrain rostroventral medulla 




transmission (West et al., 2015). Injury and disease may alter the relative activation of these 
opposing systems resulting in a pro-nociceptive condition. These descending mechanisms 
have been explored in rats (Bannister et al., 2017), rabbits (Harris, 2016), and man (Pud et 
al., 2009), and are assumed present in all mammalian species, however prior to our work 
described later, investigations had not previously been performed in dogs.  
1.5 Maladaptive Pain 
Pain which occurs “in the absence of ongoing noxious stimuli and does not promote healing 
and repair” has been termed ‘maladaptive’ by clinicians in the pain field (Dickinson et al., 
2010) and postulated to represent a disease process in itself (Tracey & Bushnell, 2009). In 
contrast other writers have argued that such forms of pain remain linked to evolutionary 
advantages for individuals (Walters, 2019). Regardless of whether this state is regarded as 
physiological or pathophysiological, ethical appraisal (Table 1) demands that in our 
domesticated animals, where ‘maladaptive’ pain has come to be separated from its 
potential evolutionary benefits, it should be managed effectively. The mechanisms of 
peripheral and central sensitisation summarised above may contribute to maladaptive pain 
within days of injury or, conversely, never at all, dependent on individual susceptibility 
(Edwards, 2005). Whilst NSAIDs have proven efficacy in the management of osteoarthritis 
associated pain in dogs (Sanderson et al., 2009), there is less evidence on appropriate 
strategies for management of cases which show inadequate response to NSAIDs  (Moore, 
2016), and in human medicine treatment of chronic pain remains challenging (Turk 2002).  
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1.6 Persistent Pain 
The term ‘persistent pain’ is likely to be preferable to that of ‘chronic pain’ which, for 
human patients, is defined temporally as “continuing or recurrent pain lasting for longer 
than 3 months” (Treede et al., 2015). Persistent pain can be generated by continuing 
nociceptive or inflammatory pain, by neuropathic states, or by nociplastic changes within 
peripheral or central nervous systems; these may persist despite tissue healing sooner than 
3 months, thus the temporal course of a painful condition cannot predict the underlying 
mechanisms which produce it. Clinical examples of persistent pain in dogs and cats are 
common and widespread, and include osteoarthritis, dental and periodontal lesions, aural 
disease, vertebral and spinal cord conditions, neoplasia, visceral pain, dermatological 
disease, and neuropathic conditions (Bell et al., 2014; Epstein, 2020; Menchetti et al., 2020; 
Monteiro 2020) 
1.7 Welfare 
Welfare is a multidimensional construct, encompassing physical and psychological 
dimensions. Broom (1986) defined this construct by writing “the welfare of an individual is 
its state as regards its attempts to cope with its environment”. Initial approaches to 
promotion of welfare focussed on the minimising of negative states (hunger, thirst, 
discomfort, pain) and enabling the expression of normal behaviour (five-freedom model)2. 
Later thinking has highlighted the value of positive affective states in animals (Mellor, 2015) 
as a component in the provision of “a good life” for animals (as distinct from a “life worth 
                                                        
2 https://webarchive.nationalarchives.gov.uk/20121010012427/http://www.fawc.org.uk/freedoms.htm 




living”, provided for by the five-freedom model) (Yeates, 2017). Assessment of welfare 
compromise over five domains (Mellor and Reid, 1994) has been modified to include 
considerations of positive affective states (Mellor and Beausoleil, 2015). Pain may impact 
welfare, and therefore quality of life (Broom, 2007), via both health related and affective 
domains (Mellor and Beausoleil, 2015) reflecting not only the sensory-discriminative aspects 
(location, intensity, character) of nociceptive stimuli (Botreau et al., 2007; Belshaw et al., 
2015), but additionally their affective-motivational consequences (Auvray et al., 2010). 
Development of health related quality of life assessment tools has recently been 
undertaken in dogs (Reid et al., 2013). Such tools would be hoped to capture information 
relating to the impact of painful conditions in dogs, in relation to a more global appraisal of 
the dogs’ welfare.  
 
1.8 Summary 
Nociception is an essential sense in free ranging animals, enabling the avoidance of harm 
related to suprathreshold nociceptive stimuli and in mammals, amongst other animals, 
associated affective components of nociception permit learning and the development of 
strategies to avoid similar stimuli in future. The physiology underlying nociception is 
comparable across mammalian species. Tissue injury induces an upregulation of nociception 
via peripheral and central sensitisation, with an evolutionary advantage in avoiding use of 
damaged tissues whilst healing occurs. Upregulation of nociception following healing, or in 
the absence of tissue injury is considered maladaptive, whilst ongoing disease processes 
such as osteoarthritis or neoplasia may result in persistent pain states. Both adaptive and 
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maladaptive pain have negative impact on welfare of domesticated animals and it is 
increasingly recognised that effective pain management is essential in the provision of 
humane care of animals.  
2. Papers for consideration and accompanying commentary 
2.1 Comparison of the efficacy of different opioids in managing surgical pain in 
canine patients.  
 
As alluded to earlier, successful management of pain necessitates correct identification and 
assessment of pain, together with good evidence for chosen interventions.    
Pain assessments incorporating behavioural indicators are more sensitive than those relying 
on physiological measurements in dogs (Holton et al., 1998a; Holton et al., 2001). The 
absence of pain may be therefore inferred by normal behaviour of the individual, however 
altered behaviour may not be specific for pain, particularly when effects of sedation, or 
anxiety resulting from unfamiliar environments and stimuli are considered (Short, 1998). 
The evaluation of perioperative pain has been reported to be improved by interaction of the 
assessor with the animal and palpation of the surgical wound, compared to observation 
alone (Shih et al., 2008), therefore, if clinicians are in doubt as to the presence or absence of 
pain, palpation of potentially painful areas and encouraging the animal to move are likely to 
assist in diagnosis. Whilst assessments by experienced observers may reliably identify pain 
and estimate its magnitude, they are subject to significant inter-individual variability (Holton 
et al., 1998b). Given that a number of veterinary staff may treat and care for dogs whilst 
hospitalised, standardised clinical pain assessments should ideally minimise observer bias 




Glasgow Composite Measure Pain Scale was developed using psychometric principles to 
optimise validity, reliability, and responsiveness (Holton et al., 2001), and weighting of items 
in the scale described by Morton et al., (2005), providing a tool for research. A clinical tool 
was further developed from this, the short-form Glasgow Composite Measure Pain Scale 
(Reid et al., 2007), for which a suggested intervention pain score was determined (Reid et 
al., 2007). Use of this scale was subsequently validated in post-operative soft tissue and 
orthopaedic cases (Murrell et al., 2008), enabling clinical research to incorporate these 
scales as an outcome measure with a high degree of confidence that they will discriminate 
differing degrees of post-operative pain (Reid et al., 2018). Application the short form 
Glasgow Composite Pain Scale, was used to evaluate clinically relevant differences in 
analgesia induced by two opioid drugs in dogs in paper 1. 
 
2.1.1 Paper 1. Hunt, J.R., Attenburrow, P.M., Slingsby, L.S., Murrell, J.C., 2013. 
Comparison of premedication with buprenorphine or methadone with meloxicam for 
postoperative analgesia in dogs undergoing orthopaedic surgery. Journal of Small 
Animal Practice 54, 418–424.  
 
Prior to publication of this prospective, randomised positively controlled clinical study, few 
data were available to guide veterinary surgeons as to the relative efficacy of available 
opioid analgesics for the management of pain associated with orthopaedic surgery in dogs. 
Buprenorphine 0.007-0.02 mg kg -1 was considered to provide equivalent analgesia to 
morphine 0.3-0.8 mg kg-1 for a range of orthopaedic surgeries when assessed using a 4 point 
simple descriptive scale (SDS) to evaluate pain (Taylor & Houlton, 1984). Equivalent 
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analgesic efficacy was demonstrated between 0.01 mg kg -1 buprenorphine and 0.3 mg kg -1 
morphine for dogs undergoing arthrotomy and assessed by a visual analogue scale (VAS) 
(Brodbelt et al., 1997). Both of the above studies were performed prior to validation of 
multidimensional acute pain scales in dogs, therefore data collected would have been 
subjective, and challenging to extrapolate to other populations. At the time that this 
research had been conducted the anaesthetics thiopental and halothane were commonly 
used, and these drugs were used in both of the above studies. By 2006 the most commonly 
used intravenous and volatile anaesthetic agents in dogs and cats were propofol and 
isoflurane (Brodbelt 2006). Recovery from thiopentone anaesthetic induction is significantly 
longer compared with recovery from propofol (Ko et al., 1999), whilst recovery from 
halothane anaesthesia has been reported to be significantly longer compared with 
isoflurane in dogs (Hellebrekers, 1986). Potentially, longer recovery times associated with 
thiopentone and halothane anaesthesia employed in these two studies may also have 
confounded the assessment of pain in the early postoperative period. Therefore, evaluation 
of the analgesics buprenorphine and methadone when used in combination with modern 
anaesthetic techniques and validated multidimensional pain scales was desirable to reflect 
current anaesthetic practice and fill the gap in the literature. 
Buprenorphine has marketing authorisation for post-operative analgesia and sedation in 
dogs in the UK at a dose of 10-20µg kg-1; and, at the time this study was conducted, was the 
most frequently prescribed opioid for premedication of dogs in the UK (Brodbelt, 2006), 
whilst in 2013 a racemic mixture of D- and L- methadone had recently received marketing 
authorisation for analgesia and premedication prior to general anaesthesia in dogs at doses 




Pharmacological differences between these two molecules suggested that there may be 
appreciable differences in efficacy for clinical pain. Levomethadone (L-methadone) 
functions as a full agonist (i.e. able to generate a maximal response ) at the µ opioid 
receptor (Davis & Inturrisi, 1999), whilst buprenorphine’s action is that of a partial agonist 
(i.e. unable to elicit a maximal response at full receptor occupancy) (Pick et al., 1997). Both 
drugs interact with additional receptor types. The dextrorotatory isomer of methadone (D-
methadone) exhibits non-competitive NMDA receptor antagonism (Davis & Inturrisi, 1999), 
and methadone inhibits synaptic serotonin reuptake (Gillman, 2005). The contribution of 
NMDA antagonist activity of racemic methadone to anti-nociception is unclear (Carpenter et 
al., 2000), but it has been demonstrated to prevent morphine tolerance and NMDA-induced 
hyperalgesia (Davis & Inturrisi, 1999). 
Buprenorphine functions as an agonist at the nociceptin/orphan FQ receptor (Lutfy & 
Cowan, 2004), and activation of this receptor by buprenorphine is considered to antagonise 
µ opioid receptor antinociception (Khroyan et al., 2009). Rodent nociceptive threshold 
testing models demonstrate biphasic (Pick et al., 1997) or bell shaped (Raffa & Ding, 2007) 
dose response curves associated with buprenorphine administration. It is postulated that 
these characteristics are the result of nociception/orphan FQ mediated attenuation of µ 
opioid anti-nociception (Khroyan et al., 2009). 
The clinical relevance of the properties of buprenorphine are not fully understood. In a 
study of dogs undergoing ovariohysterectomy, no difference in VAS pain scores was 
identified in dogs treated with 40µg kg-1 buprenorphine compared with 20µg kg-1 (Slingsby 
et al., 2011); suggesting that buprenorphine associated analgesia had reached a plateau at 
the 20 µg kg-1 dose, but that analgesia was not antagonised at the higher dose. However, 
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antagonism of sufentanil (a potent µ opioid agonist) antinociception by buprenorphine has 
been demonstrated in dogs undergoing ovariohysterectomy (Goyenechea Jaramillo et al., 
2006). 
Administration of methadone (0.3 mg kg-1) by intravenous and extradural routes in dogs 
undergoing surgical repair of cruciate ligaments (Leibetseder et al., 2006) demonstrated 
that both intravenous methadone and extradural methadone provided adequate analgesia 
for approximately six hours in this study. In that study, extradural administration of 
methadone significantly reduced the concentration of isoflurane required to maintain 
anaesthesia, compared to intravenous methadone. This suggests that the intraoperative 
anti-nociception associated with extradural administration was more profound than that 
elicited by intravenous methadone.  
 
Given the differences between the two drugs, we designed the study to rigorously compare, 
using validated pain scoring tools, the analgesic effects of either 20µg kg-1 buprenorphine 
(group B) or 0.5mg kg-1 methadone (group M) intramuscularly at the time of premedication, 
in conjunction with meloxicam administered subcutaneously following induction of 
anaesthesia. Pain was assessed using the Short Form Glasgow Composite Pain Scale (GCPS-
SF) and dynamic interactive visual analogue scale (DIVAS). The results of the study 
demonstrated clinically relevant differences in post-operative pain scores between dogs 
treated with the two analgesics. Over the course of the observation period mean pain 
scores were higher in group B compared to group M as assessed by both DIVAS and GCPS-
SF. At time points 210, 240, 360 and 480 minutes post premedication, mean GCPS-SF was 
significantly higher in group B compared to group M. The differences in pain scores had real-




with buprenorphine required additional analgesia prior to scheduled post-operative 
analgesics, compared with dogs treated with methadone. This work also demonstrated that 
significant numbers of dogs undergoing orthopaedic surgery and treated with systemic 
analgesics were likely to require additional analgesia prior to scheduled dosing, 
underscoring the importance of assessing pain in individual patients and considering 
alternate analgesic strategies, such as locoregional techniques (Bini et al., 2018).  
 
Subsequent work has demonstrated similarly reduced pain scores and requirement for 
additional analgesics in both dogs (Shah et al., 2018b) and cats (Shah et al., 2018a) 
undergoing ovariohysterectomy treated with methadone compared with buprenorphine, 
although smaller studies in mixed sex cats undergoing castration or ovariohysterectomy 
have not identified such differences (Bortolami et al., 2013, Slingsby et al., 2015). A possible 
explanation for this discrepancy is the inclusion, in the latter two studies, of both castration 
and ovariohysterectomy surgeries, thus increasing variability of the associated surgical pain 
(Quarterone et al., 2017); and the evaluation of three opioid groups (methadone, 
buprenorphine, and butorphanol), thereby reducing the power of the studies to detect 
differences.  
 
The statistical handling of Glasgow Composite Pain Scale (GCPS-SF) data employed in paper 
1 relied on transforming the recorded whole number scores to a fraction, in order to 
account for the application of different denominator values in dogs which were ambulatory 
compared with those which were not. This approach enabled the longitudinal evaluation of 
dogs from the early (non-ambulatory) post-operative period to the study conclusion 8 hours 
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post pre-medication. However, this transformation has been criticised, as conversion to a 
fraction may alter the measurement properties of the scale (Reid, 2019; personal 
communication). An alternative proposed approach would be to score any dogs that remain 
too heavily sedated to move as maximal in the movement category (Reid, 2019; personal 
communication) though this may over-estimate pain scores. A possible consequence of this 
approach may be the overuse of analgesics, which may be associated with vomiting or a 
delayed return to eating (Bini et al., 2018). 
Future studies which evaluate agreement between these two different approaches of 
processing GCPS-SF scores, compared with a dynamic interactive visual analogue scale 
completed by the same observer, might provide further evidence as to the most 



















2.2 Defining the Prescribing of Analgesics in Clinical Practice 
 
Given clear evidence that methadone acts as a more efficacious analgesic, at authorised 
doses, compared with buprenorphine in dogs, it was important to document the analgesic 
strategies currently used by veterinary surgeons in the UK and identify areas where 
education or training could benefit animal welfare. The provision of analgesia to dogs and 
cats under veterinary care has historically been inadequate (Capner et al., 1999; Lascelles et 
al., 1999), and failed to meet client expectations (Demetriou et al., 2009). However 
increased availability of analgesics with marketing authorisation for use in dogs and cats and 
wider access to continued professional development on the subject of analgesia may be 
expected to improve prescribing rates in the 17 years since the previous studies were 
performed. Evidence from other countries had documented increasing levels of 
perioperative analgesic prescription over time to cats and dogs by veterinary surgeons 
(Joubert, 2006; Hewson et al., 2006); alongside some information suggesting improved 
analgesic treatment of cats undergoing neutering surgery from the UK, together with 
Australia and New Zealand (Farnworth et al., 2014). Previous work had also demonstrated 
reduced prescription of analgesics to cats compared with dogs; and higher analgesic 
prescription rates amongst female veterinary surgeons and veterinary surgeons who had 
graduated more recently (Capner et al., 1999; Lascelles et al., 1999). It was therefore 
important that a comprehensive survey of the profession, which could be related to the 
earlier findings of Capner et al. (1999) and Lascelles et al. (1999), was undertaken in the UK 





2.2.1 Paper 2. Hunt, J.R., Knowles, T.G., Lascelles, B.D.X., Murrell, J.C., 2015. 
Prescription of perioperative analgesics by UK small animal veterinary surgeons in 
2013. Veterinary Record 176, 493.  
 
In order to determine whether provision of analgesia overall to cats and dogs had increased 
in the UK since 1999, a cross-sectional survey was designed and distributed. The primary 
research question was whether provision of perioperative analgesia to cats and dogs overall 
had increased in the UK since the previous survey in 1999. Secondary research questions 
included whether use of multi-modal analgesic strategies had increased compared with 
previous findings, whether a discrepancy remained between the prescription of analgesics 
for cats compared with dogs, and whether levels of analgesic prescription continued to be 
influenced by gender and duration of qualification of the veterinary surgeon.  
Printed copies of the survey were distributed, along with postage paid envelopes, to four 
thousand randomly selected veterinary surgeons engaged in small animal practice 
(approximately 20% of the total number of veterinary surgeons registered with the Royal 
College of Veterinary Surgeons). One hundred surveys were also distributed to members of 
the Association of Veterinary Anaesthetists (AVA) to address the question of whether 
additional training in anaesthesia/analgesia impacted prescribing practice. The survey was 
also made available online. Reported advantages of producing a written format 
questionnaire include “the ability to sample from a larger number of respondents at lower 
cost in a given time frame compared to, for example, telephone or face-to-face interviews, 
and a reduced risk of variability in response related to questioning by different interviewers” 
(Lavrakas, 2008). Disadvantages include the fact that “data processing recorded by mail 
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questionnaires is laborious and time consuming and there is no ability to control 
presentation order of items; respondents can examine the contents of the entire instrument 
before answering any question” (Lavrakas, 2008). 
 
Data from 661 paper questionnaires (completion rate 16.1%) and 59 online questionnaires 
were analysed, with respondents grouped according to time since graduation, gender, and 
AVA membership.  
 
The results of the survey enabled us to conclude that significant improvements in analgesic 
provision had occurred since the previous United Kingdom surveys, but some discrepancies 
between respondent groups remained. All respondents indicated that at least one opioid 
and one NSAID analgesic were available, compared with previous data of 91% and 94% 
respectively (Lascelles et al., 1999). Consistent with previous data (Lascelles et al., 1999; 
Brodbelt, 2006), buprenorphine remained the opioid most widely available (98.9% of 
respondents), however 81.8% of respondents stated that they were able to prescribe a full 
µ opioid agonist in their practice. Around three-quarters of respondents prescribed a 
combination of opioids and NSAIDs (multi-modal analgesia) to dogs and cats undergoing 
surgery; significantly more than the 30 per cent of respondents who employed multi-modal 
analgesia in the previous survey (Capner et al., 1999). Fewer respondents administered 
perioperative opioids to cats (81.8%) undergoing routine surgeries compared with dogs 
(90.5%), and fewer respondents provided post discharge NSAIDs to cats (33.4%) compared 
with dogs (75.1%) following routine surgery, suggesting continued discrepancies in analgesic 
use between species. Ovariohysterectomy and castration surgeries were considered by 




the reported differences in prescribing. Male veterinary surgeons were less likely to 
prescribe perioperative NSAIDs in cats (94.4%) and post-operative NSAIDs in dogs (68.4%) 
compared to female veterinary surgeons (99.4 % and 78.4%, respectively). Prescribers of 
perioperative opioids to dogs, and perioperative opioids and NSAIDs to cats, were more 
recently graduated compared to non-prescribers.  
 
Evaluating the impact of further education or interest in anaesthesia and analgesia, 
significant differences were identified between AVA members and other respondents. A 
higher proportion of AVA members (92.6%) prescribed postoperative NSAIDs to dogs (non-
AVA 74.3%) and cats (AVA 77.8%, non-AVA 31.5%) undergoing routine surgeries. AVA 
members were significantly more likely to state that they routinely employed regional local 
anaesthetic techniques, although they were no more likely than non-members to employ 
skin infiltration with local anaesthetic. Members of the AVA were also significantly more 
likely to state that they had previously utilised continuous infusions of analgesics including 
ketamine, α2 agonists, lidocaine, and combinations of these with opioids. However, 
availability of equipment for the controlled delivery of such infusions was reduced for non-
AVA members (36.2%) compared with AVA members (100%), which may have reduced the 
opportunity for non-AVA members to safely utilise such strategies. Interestingly, AVA 
members were significantly less likely (24.1%) to prescribe tramadol perioperatively to dogs 
undergoing orthopaedic surgery, compared with non-AVA members (59.5%). Although there 
are some reports that parenteral tramadol 2mg kg-1 provides effective analgesia for 
orthopaedic surgery in dogs (Yazbek & Fantoni, 2005; Vettorato et al., 2010), oral 
administration of 4-5 mg kg-1 is less effective than NSAIDs alone (Davila et al., 2013). These 
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findings would be consistent with the pharmacokinetics of tramadol in dogs, which exhibits 
bioavailability of approximately 30% following oral administration (Giorgi et al., 2009). 
Higher oral doses (9.9mg kg-1) may be antinociceptive (KuKanich & Papich, 2011). At the 
time the survey was conducted tramadol prescription would have been as human 
formulations used ‘off-licence’ under the cascade provisions of the Veterinary Medicines 
Regulations. Since completion of the survey tramadol has been added to Schedule 3 of the 
controlled drugs regulations, and injectable and oral formulations have received marketing 
authorisation as analgesics for mild post-operative pain and acute and chronic mild soft 
tissue and musculoskeletal pain in dogs. It is currently unknown what effect, if any, these 
changes may have had on prescribing.  
Pain assessment tools were routinely used by higher proportions of AVA members (dogs 
89.3%, cats 64.3%) compared with non-members (14.9% and 15.1%, respectively). Gender 
and interval since graduation were not associated with the use of pain assessment tools. A 
higher proportion of pain assessment tool users compared with non-users prescribed 
perioperative opioids to dogs (96.0% compared with 89.0%) and cats (90.0% compared with 
80.0%) undergoing routine surgery, and postoperative NSAIDs to cats (47.5% compared with 
30.2%). 
 This work documented significant improvements in the provision of analgesia to companion 
animals treated by UK veterinary surgeons over the course of 15 years. The increasing 
availability of videos demonstrating local anaesthetic techniques, such as those supported 
by the World Small Animal Veterinary Association3,  would be hoped to improve the uptake 
                                                        





of these strategies by the veterinary profession, and further surveys should be planned to 
evaluate the impact of making such continued education available in this form.  
  
  



















































2.3 Defining adverse events related to prescription of non-steroidal anti-
inflammatory drugs 
 
Non-steroidal anti–inflammatory drugs are effective antipyretics and analgesics in acute and 
chronic inflammatory pathologies (Slingsby & Waterman-Pearson, 2000; Lascelles et al., 
2001; Lascelles et al., 1998; Moreau et al., 2003). In Paper 2 these drugs were shown to be 
the class of perioperative analgesics most commonly prescribed to dogs and cats (Hunt et 
al., 2015), but they may be associated with a range of adverse events. An adverse event is 
defined by the International Cooperation on Harmonisation of Technical Requirements for 
Registration of Veterinary Medicinal Products (VICH) as “any observation in animals, 
whether or not considered to be product-related, that is unfavourable and unintended and 
that occurs after any use of Veterinary Medicinal Product (VMP) (off-label and on-label 
uses)”. Discussion of the risks versus benefits of NSAID prescription may be hampered by a 
lack of published data on the likelihood of adverse events in animals.  
Non-steroidal anti-inflammatory drugs act by inhibiting cyclo-oxygenase enzymes, therefore 
reducing the formation of prostaglandins from arachidonic acid located in cell membranes. 
Cyclo-oxygenase (COX) exists in at least two forms (Vane et al., 1998), COX-1 mainly 
functioning in a constitutive homeostatic role and COX-2 an inducible form responsible for 
increasing the production of prostaglandins in inflammatory states. This knowledge has led 
to the development of COX-2 selective and specific drugs in an attempt to reduce the side 
effects associated with the reduction of homeostatic prostaglandins in organs such as the 





A variety of NSAID molecules have marketing authorisation for treatment of pain and 
inflammation in dogs and cats, ranging from COX-1 selective drugs such as ketoprofen, 
through COX-2 preferential drugs such as meloxicam and carprofen (Streppa et al., 2002) to 
COX-2 selective drugs such as firocoxib, robenacoxib, mavacoxib and cimicoxib (McCann et 
al., 2004; King et al., 2010; Carmichael, 2011). Whilst theory suggests that improved safety 
would be associated with the use of COX-2 selective drugs, there is limited evidence of the 
frequency and severity of adverse events (AEs) related to NSAIDs with marketing 
authorisation for long term use in the target population of cats and dogs, and none which 
documents improved safety resulting from the use of COX-2 selective drugs rather than 
COX-2 preferential drugs. In man, COX-2 selective drugs were shown to be associated with a 
lower risk of gastrointestinal adverse events compared with non-selective NSAIDs (Moore, 
A. et al., 2013), although increased risk of cardiovascular adverse events associated with the 
COX-2 selective rofecoxib (Baron et al., 2008) led to the withdrawal of this drug from the 
market. Subsequent work has identified that most NSAIDs are associated with an increased 
risk of cardiovascular events in man (Barcella, et al., 2019). 
 
A meta-analysis of 14 studies assessing treatment of osteoarthritis in dogs of more than one 
month’s duration, performed by Innes et al., (2010), reported calculated experimental 
(adverse) event rates ranging from 0 to 0.31, though the failure of many studies to include a 
placebo group limited the ability to estimate ‘numbers needed to harm’.  The rate of 
adverse events did not appear to increase with increasing duration of treatment, however 
the authors concluded that “robust data on the safety of long-term NSAID use are lacking in 
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large numbers of dogs”. Only one AE which was considered serious was reported in the 
trials assessed, which was an episode of toxic hepatitis in a Labrador.  
 
Data from field trials of meloxicam at authorised doses (Boehringer Ingelheim Vetmedica, 
2003) indicate a reported incidence of 28% for vomiting in 109 dogs during a two week 
treatment period, compared to an incidence in the control group of 13% (n=115) (p = 
0.005), though the incidence of diarrhoea/soft stools was not different between groups 
(14% and 10%).  Over a four week study period adverse gastrointestinal side effects were 
noted in 4 out of 38 dogs (11%) administered meloxicam at authorised doses (Doig, 2000). 
Lower incidences of vomiting in dogs treated with carprofen over a two week period (Pfizer, 
2002) (3.1% of 129) or placebo (3.8% of 132) were reported, incidence of diarrhoea in this 
study was also low (3.1 and 4.5 %).  
Incidence of vomiting over a 30 day treatment period with firocoxib was 4% in 128 dogs, 
contrasted with the positive control etodolac (7% in 121 dogs) (Turner, 2004). 
 
Autefage et al., (2011) reported treatment of 39 dogs, with clinical and radiographic signs of 
osteoarthritis, with 5mg kg-1 firocoxib over a period of 360 days. One dog was withdrawn 
from the trial due to diarrhoea, one dog suffered a fatal perforating gastric ulcer a few days 
after accidentally being treated with a double dose of firocoxib, and two dogs were 
withdrawn from the study due to elevations in serum creatinine.  
 
In a non-inferiority study of robenacoxib and carprofen in a population of osteoarthritic 
dogs the most frequent adverse events reported were diarrhoea or vomiting (robenacoxib 




which were mostly benign and transient. Blood in the faeces was noted in one of 125 dogs 
receiving robenacoxib and two of 63 dogs receiving carprofen, again no significant 
difference in frequency of this AE was identified between groups (Reymond et al., 2012).  
 
These varying estimates of incidence are undoubtedly related to the relatively small 
(compared to the number of prescriptions for these drugs issued) sample sizes. However as 
these studies, combined with data from case reports (Reed, 2002; Duerr et al., 2004; Enberg 
et al., 2006) show, gastrointestinal side effects are not uncommonly encountered in dogs 
treated with NSAIDs.   
 
In an experimental toxicological study involving three male and three female dogs treated 
with intravenous meloxicam 0.2 mg kg-1 (double the recommended maintenance dose) for 3 
days (Boehringer Ingelheim Vetmedica, 2003), one dog vomited on the third day of 
treatment. At post-mortem examination all three female dogs exhibited areas of 
congestion, inflammation and haemorrhage in the colon, ileum, and caecum. Whilst the 
sample size is too small to draw conclusions, it suggests the potential for sex related 
differences in the occurrence of NSAID related AEs. Evidence from medical literature also 
suggests that female patients have an increased risk of serious gastrointestinal AEs  (Neutel 
et al., 1999). 
 
In addition to gastrointestinal adverse effects, other reported potential consequences 
associated with the use of NSAIDs in dogs at recommended doses include hepatocellular 
necrosis (Nakagawa et al., 2005), toxic hepatitis (Moreau et al., 2003; MacPhail et al., 1998), 
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prolongation of bleeding times (Luna et al., 2007), leucocytosis, fever, elevations in gamma 
glutamyl transferase, blood urea nitrogen and total calcium (Boehringer Ingelheim 
Vetmedica, 2003). At doses of meloxicam five times higher than recommended for three 
days two out of three female dogs developed acute renal failure accompanied by clinically 
significant increases in urine protein concentration. Dogs treated with five times the 
recommended dose also displayed increases in alkaline phosphatase (ALP) and serum 
calcium, and decreased serum total protein (Boehringer Ingelheim Vetmedica, 2003). In a 
study of firocoxib administered at five times the recommended dosage for 6 months, 
transient elevations in white blood cell and platelet counts and decreases in albumin were 
reported, which had returned to normal levels by the completion of the study (Turner, 
2004). In that study, thalamic vacuolation was reported to be more severe in dogs treated 
with five times the recommended dosage of firocoxib compared to control dogs that 
received placebo. Although mean ALP concentrations remained within normal ranges for all 
groups, concentrations were significantly higher in dogs treated with 3x and 5x the 
recommended dosage compared to controls (Turner, 2004). In dogs treated with 5 to 10 
times the recommended doses of carprofen for 6 weeks, hypoalbuminaemia was reported 
in some dogs (Pfizer, 2002). 
 
Data on adverse events during treatment of naturally occurring osteoarthritis in cats are 
similarly sparse, though there is some evidence that cats experiencing AEs related to 
meloxicam were treated for longer durations than cats not experiencing AEs (Charlton et al., 
2013).  In that study 4 out of 22 (18%) cats experienced adverse events related to daily 
treatment with a mean dose of 0.027 mg kg-1 meloxicam, after a median duration of 




necessitated stopping treatment. Daily doses of meloxicam from 0.01-0.03 mg kg-1 were 
administered to 40 osteoarthritic cats for a mean of 5.8 months (Gunew et al., 2008). 
Gastrointestinal upset related to meloxicam administration was reported in 2 out of 46 cats 
in that study.  
 
Toxicity studies of robenacoxib in cats cite soft stools as the most frequent adverse event 
related to treatment, occurring in up to a third of animals treated with 2-10 times the 
recommended dose of robenacoxib, but found that this was not different to the incidence in 
placebo treated animals (King et al., 2011). 
 
When used at lower than authorised dose rates in a cohort of older cats with osteoarthritis 
(Gowan et al., 2011) meloxicam did not appear to accelerate the progression of pre-existing 
renal disease, and did not appear to increase the incidence of renal disease in a cohort of 
cats without renal disease at the beginning of the study.  
 
During 35 days of treatment with robenacoxib in cats at 3 and 5 times the recommended 
dosage transient decreases in mean cell haemoglobin concentration compared to placebo 
were identified after 14 days, but there was no difference to placebo after 35 days (King et 
al., 2011). In this study minor decreases in activity of alanine aminotransferase and 
aspartate aminotransferase were also reported in the 5 x dose group. A report of an 




Experimentally, development of NSAID induced duodenal ulceration in cats has been shown 
to be increased by insoluble dietary fibre and decreased by administration of 5-lipoxygenase 
inhibitors, leukotriene antagonists and cholinergic antagonists (Satoh et al., 2009). 
 
In human population studies increased age, increased dose of NSAID, and a short term (less 
than 1 month) history of taking NSAIDs were associated with increased risk of 
hospitalisation for gastrointestinal bleeding (Lanza et al., 2009). Increased susceptibility to 
NSAID induced GI ulceration has also been demonstrated with age in rats (Hong et al., 
2012).  
 
The government body responsible for collating details of adverse events related to 
veterinary medicinal products, the Veterinary Medicines Directorate (VMD), publishes an 
annual summary of information4, however no previous work has endeavoured to estimate 
the frequency of adverse events related to administration of veterinary medicinal products, 
nor to relate risk of adverse events to demographic variables such as age and sex. To this 
end, an analysis of the relative frequencies of adverse events, associated with different 
NSAID molecules with marketing authorisation for use in dogs and cats and reported to the 
VMD, was undertaken. 
 
 
                                                        
4 https://www.gov.uk/government/collections/veterinary-medicines-pharmacovigilance-annual-review-





2.3.1 Paper 3. Hunt, J.R., Dean, R.S., Davis, G.N.D., Murrell, J.C., 2015. An analysis of 
the relative frequencies of reported adverse events associated with NSAID 
administration in dogs and cats in the United Kingdom. The Veterinary Journal 206, 
183–190. 
 
Randomised controlled clinical studies are designed to possess adequate statistical power to 
investigate the efficacy of a drug, but will be underpowered to investigate the incidence of 
rarely occurring AEs (Tramèr et al., 2000). Additionally, reporting of AEs within clinical trials 
may not always be complete (Edwards et al., 1999). Given the documented widespread 
prescription of NSAIDs and lack of evidence relating to AEs discussed above, there was a 
clear need to better understand the likelihood of drug associated adverse events.  
Following a literature review (summarised above), we hypothesised that the overall rates of 
NSAID related side effects in target populations of cats and dogs would be less than 10%, 
and that COX-2 selective drugs would be associated with a lower incidence of 
gastrointestinal adverse events than COX-2 preferential and COX-1 preferential drugs. We 
also hypothesised that increasing age would be associated with an increased risk of 
gastrointestinal adverse events.  
 
The original aims of the study were  
1. To document the incidence of adverse events associated with the use of carprofen, 
meloxicam, firocoxib, robenacoxib, mavacoxib and cimicoxib (in dogs) and 
meloxicam, carprofen and robenacoxib (cats) as reported to the Veterinary 
Medicines Directorate by drug companies, veterinary surgeons or animal owners.  
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2. To determine any differences in incidence of adverse events between the various 
NSAID molecules.  
 
3. To determine (by a prospective trial incorporating an owner questionnaire) the 
incidence of adverse events in a first opinion population of animals prescribed an 
NSAID molecule for osteoarthritis.  
 
4. To determine any differences in incidence of reported adverse events compared to 
the incidence expected as a result of the prospective trial.   
 
5. Further analyse the data to determine if any breed or age associations are evident.  
 
Our initial approach was to discuss the proposed project with the co-ordinator for the 
National Office of Animal Health (NOAH), an industry body which represents the majority of 
the pharmaceutical companies producing veterinary medicines in the United Kingdom.  
The result of this approach was that a number of manufacturers expressed concerns 
regarding the disclosure of data related to the size of their market, and any skewing of data 
related to frequency of adverse events (e.g. more recent marketing authorisation). The 
recommendation from NOAH was to approach the VMD so that data would be provided in a 
standardised format for all manufacturers of veterinary medicines. Following writing to the 
VMD to request information, we were invited to a meeting to discuss the project. Following 
our presentation, which highlighted the aims of determining valid estimates for the 




factors associated with increased risk of AEs, the VMD agreed to provide data in a limited 
form, to avoid any potential contravention of commercial sensitivity. Cumulative 
frequencies of AEs, since the date of marketing authorisation, were provided for each drug 
molecule. The VMD calculated the frequencies by dividing the number of reports of AEs by 
the number of doses of each product used. To calculate the number of doses, the volumes 
of products sold were divided by the average volume per dose, assuming an average dog 
weight of 20kg and cat weight of 5kg. Adverse events were classified according to 
Veterinary Medicinal Dictionary for Drug Regulatory Authorities (VeDDRA) terms and 
provided in a spreadsheet file.  
Unfortunately, the time required to obtain the pharmacovigilance information precluded 
conducting the intended prospective study to document the incidence of AEs associated 
with new NSAID prescriptions in first opinion practice. Demographic data associated with AE 
reports was also not made available, therefore no descriptive analysis of the affected 
animals was possible. 
From the information provided we were able to identify the ten most commonly reported 
AEs for each molecule, compare the reported frequencies of AEs between coxibs and non-
coxibs administered orally to dogs, compare the reported frequencies of AEs between oral 
and injectable formulations across both species, analyse the correlation between frequency 
of reported AEs and time since marketing authorisation, and compare the reported 
frequency of AEs associated with oral NSAID administration between cats and dogs.  
We identified that there were no significant differences in reported frequency of AEs 
associated with oral NSAID administration between cats and dogs. There was a significant 
negative correlation between reported frequency of AEs and time since marketing 
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authorisation. Reported frequencies of AEs were higher in association with coxibs compared 
with non-coxibs in dogs, and injectable compared with oral formulations in both dogs and 
cats. We also identified that convulsions were reported as an AE associated with NSAIDs in 
dogs and cats.  
 
Without knowing the size of the population at risk, it was not possible to draw any 
conclusions regarding the incidence of AEs related to NSAID prescription, therefore the 
relative frequency of reports, as a fraction of the estimated number of doses sold (but not 
administered) was used as a measure to compare the scale of AEs associated with different 
molecules and formulations. Unfortunately, given the assumptions that were required to be 
made to calculate the relative frequencies of AEs, these figures are in no way comparable to 
incidences of AEs reported in previous studies, therefore accurate estimates for the 
incidence of NSAID related AEs remain to be determined.  
 
Although the data were challenging to interpret due to a number of potential confounding 
factors, including the time elapsed since marketing authorisation, severity of the adverse 
event, and clinical circumstances likely to be associated with differing routes of 
administration, our analysis provides a basis for further studies. It is possible that data 
collected through initiatives such as VetCompass™ may provide a more valid estimate of the 
incidence of AEs which precipitate veterinary examination, compared with the passive 
surveillance system that was used to generate data for the present study. Large scale 
prospective studies to actively document AEs associated with new NSAID prescriptions and 
identify demographic risk factors for AEs would also be expected to generate useful data. 




NSAID molecules considered was unexpected. Clearly the data are insufficient to 
demonstrate causality, and these adverse events may be related to the underlying medical 
condition of the patient rather than to drug administration, but this study highlights the 
























2.4 Investigating Mechanisms of Pain in Canine Osteoarthritis 
 
In addition to negatively affecting quality of life and potentially leading to early euthanasia 
of a significant number of pet dogs (Moore et al., 2001), naturally occurring osteoarthritis 
(OA) has been proposed as a model for the human disease (Vainio, 2012). Importantly the 
pain arising from joint pathology may become exaggerated by aberrant processing (central 
sensitisation, CS) within the central nervous system (Neogi, 2013). Whilst joint pain 
associated with OA commonly responds well to NSAIDs, cases which exhibit central 
sensitisation are likely to require classes of analgesics which interact with targets expressed 
in the central nervous system. However, currently available clinical metrology instruments 
designed to evaluate pain in dogs are unable to differentiate localised joint pain from 
central sensitisation. Characterisation of pain processing in canine osteoarthritis is therefore 
desirable in order to treat canine disease adequately, and additionally to increase the 
potential for the translation of canine research to human medicine. Quantitative sensory 
testing (QST) in conscious dogs has demonstrated group-level somatosensory sensitisation 
in dogs affected by naturally occurring osteoarthritis, compared with a group of unaffected 
dogs, suggestive of central sensitisation or generalised peripheral somatosensory 
hyperalgesia (Knazovicky et al., 2016). However, generating clinically useful ranges for 
expected responses in individual healthy dogs comparable to human data (Rolke et al., 
2006) is likely to require significant effort, given that individual subject factors including 
bodyweight and condition, age, and sex have been shown to impact nociceptive thresholds 
(Harris et al., 2015; Knazovicky et al., 2016; Sanchis-Mora et al., 2017). Limitations of QST 
methods in dogs have been reported as poor feasibility in approximately 17% of dogs 




anxiety of the dog (Moore, S.A. et al. 2013), and the subjective interpretation of behavioural 
responses as an end point. 
 
Nociceptive withdrawal reflexes (NWR) represent co-ordinated activation and inhibition of 
motor units as a consequence of afferent nociceptive impulses, with the evolutionary 
objective of avoiding potentially tissue damaging stimuli. The co-ordination of NWR is 
dependent on the site of noxious stimulation (Schouenborg et al., 1994).  The reflexes occur 
at the level of the spinal cord, but are subject to descending inhibition and facilitation 
(Harris & Clarke, 2003). Recording of effector muscle electromyographic (EMG) responses of 
nociceptive withdrawal reflexes represents a quantitative method of recording the 
magnitude of motor response to a stimulus (Carstens & Ansley, 1993). Muscle 
depolarisation and contraction produces a positive and negative deflection of electrical 
potential recorded by paired intramuscular electrodes, relative to an earth electrode. This 
deflection may be recorded over a finite period of time. Assessment of the magnitude of an 
EMG response could therefore be based upon the maximum amplitude of change in 
potential, the duration of change in potential, or the product of these (integral; magnitude x 
time area under the curve). In the case of EMG recordings in response to NWR from 
sensitised subjects, changes could occur in both the magnitude and the duration of the 
deflection. Simply evaluating the mean of positive and negative components would reduce 
the calculated amplitude, therefore EMG signals are rectified (negative deviations converted 
to positive) (Kamen and Caldwell, 1996). EMG amplitudes may also be susceptible to 
artefact (Kamen and Caldwell, 1996), therefore calculation of the integral diminishes the 
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impact of high amplitude, low duration artefacts, whilst providing reliable estimate of 
myogenic activation over time.  
Central sensitisation has been evaluated in humans using EMG based techniques (Banic et 
al., 2004) and, in experimental animal models of OA, NWR facilitation (indicating CS) has 
been demonstrated (Kelly et al., 2013). Previously published work has assessed NWR in 
trained conscious or sedated research dogs (Bergadano et al., 2006; Bergadano et al., 2009). 
In order to be clinically applicable, such methods would need to be tolerated by client 
owned dogs, which are likely to be less tractable. EMG responses to nociceptive stimuli 
could be obscured by movement artefact in conscious or sedated dogs. Obtaining EMG 
recordings of sufficient quality, and minimising aversive experiences associated with the 
application of noxious stimuli (which, in addition to animal welfare considerations, may 
further modulate nociceptive transmission (Fanselow, 1986; Rhudy & Meagher, 2000)) 
would therefore most probably necessitate anaesthesia in client owned dogs.  
 
Diffuse noxious inhibitory controls (DNIC), the correlate of conditioned pain modulation 
(CPM) in humans (Yarnitsky, 2010), represent an descending endogenous inhibition of wide 
dynamic range neurons induced by a heterotopic noxious (‘conditioning’) stimulus (Le Bars 
et al., 1979; Harris, 2016). Descending noradrenergic neurons originating within the locus 
coereleus represent a key effector of these descending controls, whilst serotonergic 
neurons originating within the rostral ventromedial medulla produce pro- or anti-
nociceptive effects at the dorsal horn, dependant on the 5-HT receptor subtypes activated 
(Bannister et al., 2017). CPM is assessed experimentally in man by measuring the magnitude 




in nociceptive withdrawal reflex magnitude (Jurth et al., 2014) to a noxious (‘test’) stimulus, 
following application of the conditioning stimulus. 
 
DNIC has been elicited in animals using a number of conditioning stimuli including 
mechanical, thermal, electrical, and chemical (Le Bars et al., 1979). In man a variety of 
stimuli have been applied in conscious volunteers to elicit CPM, including immersion of the 
hand in hot water (Granot et al., 2008), intramuscular hypertonic saline (Arendt-Nielsen et 
al., 2008), ischaemia (Fujii et al., 2006), and cutaneous application of capsaicin (de Tommaso 
et al., 2007). However the most commonly reported method of activating endogenous 
descending analgesia is immersion of the hand in iced water (the ‘cold pressor test’, CPT) 
(Baad-Hansen et al., 2005; Pud et al., 2009). 
 
Considering the evidence of widespread central sensitisation to nociceptive stimuli in dogs 
affected by spontaneous hindlimb OA (Knazovicky et al., 2016); it must be recognised that 
secondary hyperalgesia may occur as the net outcome of either impaired descending 
inhibition or augmented facilitation of nociception (Millan, 2002; Bannister et al., 2015). To 
better evaluate contributory mechanisms to a global pain state, it would be desirable to be 
able to differentiate the functional status of descending inhibitory and facilitatory pathways. 
A reliable and reproducible protocol for the induction of DNIC in dogs had not been 
published prior to undertaking these investigations.  
 
During a three year BBSRC funded research project, our aims were to develop a protocol for 
the evaluation of EMG in anaesthetised dogs, to determine whether EMG recording 
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demonstrated evidence of sensitisation of NWR in dogs affected by naturally occurring 
osteoarthritis, to develop an experimental protocol for the induction of DNIC in 
anaesthetised dogs, and determine whether this was altered in dogs with OA, and to assess 
whether these findings correlated with owner completed metrology instruments, clinical 
evaluation, and QST.   
 
 
2.4.1 Paper 4. Hunt, J., Murrell, J., Knazovicky, D., Harris, J., Kelly, S., Knowles, T.G., 
Lascelles, B.D.X., 2016. Alfaxalone Anaesthesia Facilitates Electrophysiological 




The first step towards investigating nociceptive processing in dogs required us to develop 
and characterise a suitable general anaesthetic protocol which could be utilised in client 
owned dogs in the United Kingdom. Pilot work completed under the Animal (Scientific 
Procedures) Act 1986, amended 2013, and conducted at Huntingdon Life Sciences 
demonstrated that, at concentrations required to prevent arousal, both isoflurane 
inhalational anaesthesia and propofol intravenous anaesthesia were unsuitable agents as 
EMG responses to nociceptive stimulation were abolished. These findings stand in contrast 
to a study by Lervik et al. (2012), in which NWR evoked EMG responses were recorded 
during isoflurane anaesthesia. Total intravenous anaesthesia, using alfaxalone solubilised in 




2013). Our aim was to develop a suitable alfaxalone based anaesthetic protocol that was 
appropriate for administration to client owned dogs, and which would enable us to record 
EMG data whilst minimising noise due to movement artefact. We performed a prospective 
experimental study at North Carolina State University, using seven purpose bred male 
hounds who underwent NWR recording protocol under three different conditions: 
acepromazine sedation; alfaxalone sedation; and alfaxalone anaesthesia. Alfaxalone 
sedation (infusion range 0.044–0.08 mg kg-1 min-1) was defined as a reduced level of 
arousal, sufficient to maintain lateral recumbency, but retaining pharyngeal and largyneal 
reflexes. Alfaxalone anaesthesia (infusion range 0.075–0.1 mg kg-1 min-1) was defined as a 
loss of consciousness and suppression of pharyngeal/laryngeal reflexes sufficient to permit 
and maintain endotracheal intubation. The order of treatments was randomised, but the 
investigators were aware of the treatment group. The study was approved by the North 
Carolina State University Institutional Animal Care and Use Committee (IACUC). 
The magnitude of the cranial tibial EMG responses to differing protocols of increasing 
mechanical (von Frey filament) and electrical (increasing current, repeated suprathreshold 
at 60 second intervals, and repeated suprathreshold at 1Hz (designed to stimulate C-fibre 
wind-up)) stimulation of the skin and dermal tissues of the pelvic limb fourth digit were 
compared between the three different states in order to determine the effects of alfaxalone 
at sedative or anaesthetic doses on the EMG response. A multi-level modelling approach 
was used to analyse the data, to account for the hierarchical nature of the experiments. The 
results of the study demonstrated that, compared with acepromazine sedation, both 
alfaxalone sedation and anaesthesia increased nociceptive withdrawal thresholds and 
reduced the magnitude of EMG response to electrical nociceptive stimulation, whilst 
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alfaxalone anaesthesia reduced the magnitude of EMG response to mechanical nociceptive 
stimulation. Importantly, stimulus-response and temporal summation characteristics were 
preserved under both alfaxalone conditions, indicating that these techniques had potential 
utility in interrogating spinal processing of the NWR in dogs.  
Concurrent with these experiments, and approved under the same IACUC permit, we began 
to evaluate ice water immersion of the manus as a means of eliciting DNIC in dogs under 
acepromazine or alfaxalone sedation, or alfaxalone general anaesthesia. We hypothesised 
that the application of the cold water stimulus would elicit DNIC, resulting in a decreased 
magnitude of EMG response produced by a defined electrical nociceptive stimulus. 
Following completion of the previously described NWR protocols, electrical stimulation was 
delivered at 5 minute intervals and EMG responses recorded. Following three baseline 
readings, a conditioning stimulus comprising immersion of the manus and carpus in iced 
water (0-4oC) for a period of 20 minutes was applied to the distal left forelimb, which had 
been previously shaved and degreased with soap. Interdigital skin temperature 
measurements were recorded every 2 minutes using a thermocouple. Time constraints 
(maximum testing duration specified within IACUC conditions) meant that data collection 
was performed for seven dogs during acepromazine sedation, four dogs during alfaxalone 
sedation, and five dogs during alfaxalone anaesthesia. Consistent with our earlier results, 
EMG magnitude was significantly greater in acepromazine sedated dogs compared with 
alfaxalone treated dogs. The mean interdigital skin web temperature across the 3 states 
immediately prior to immersion in ice water was 31.9oC (95% CI 27.5 – 36.6oC). Skin 
temperatures reached a minimum of 4.9oC (95% CI 1.3 – 8.4oC), 13.6oC (95% CI 9.8 – 
17.3oC), and 9.4oC (95% CI 5.9 – 12.9oC) in acepromazine, alfaxalone sedated and alfaxalone 




they began to rise despite being maintained in the water bath for a further 10 minutes. Skin 
temperature measurements remained significantly higher in the alfaxalone sedated state 
compared to the acepromazine state during immersion (p=0.018); there was no significant 
difference between alfaxalone groups (p=0.25). However, the application of the 
conditioning stimulus had no effect on EMG magnitude (figures 1 and 2), suggesting that the 
stimulus did not elicit DNIC. Potential explanations for this finding are that the noxious cold 
stimulus was of insufficient intensity to recruit DNIC in dogs; that the magnitude of the test 
stimulus was too great compared to the conditioning stimulus, causing the nociceptive 
withdrawal response to the test stimulus to overcome DNIC effects, or that the time period 
during which DNIC was effective did not align with the timings of our test stimuli.  
 
Figure 1 Early (0-100ms) cranial tibial EMG responses during cold water immersion of the manus. Time point 0 represents 
the baseline (mean of responses at T-15, -10, -5, and 0). Acepromazine (n=7) sedation is represented by X, alfaxalone 
anaesthesia (n=5) by ▽ and alfaxalone sedation (n=4) by ☐. Recorded values are represented by small symbols, mean 
results are represented by larger symbols connected by lines. Variation with time was not significant. (An effective DNIC 





Figure 2 Late (100-500ms) cranial tibial responses. Time point 0 represents the baseline (mean of responses at T-15, -10, -5, 
and 0). Acepromazine (n=7) sedation is represented by X, alfaxalone anaesthesia (n=5) by ▽ and alfaxalone sedation (n=4) 
by ☐. Recorded values are represented by small symbols, mean results are represented by larger symbols connected by 
lines. Variation with time was not significant. (An effective DNIC response would be illustrated by reduced magnitude of late 
cranial tibial response during the period of ice water immersion). 
 
DNIC is elicited only by higher intensity (moderate and severe) noxious conditioning stimuli 
(Nirl et al., 2012).  Conscious, acepromazine sedated dogs responded to the conditioning 
stimulus by attempting to withdraw their limb from the stimulus, implying that the stimulus 
was perceived as aversive. However in the absence of a verbal report, the intensity of the 
conditioning stimulus was challenging to assess. Increasing the intensity (Nirl et al., 2012) or 
spatial distribution of the noxious conditioning stimulus (Bouhassira et al. 1995; Marchand 
& Arsenault 2002) can increase the recruitment of DNIC, though there is a maximum at 
which no further increase in descending inhibition is possible (Nirl et al. 2012). Application 




man (Wolf & Hardy 1941), but it is possible that increasing the spatial distribution of the 
cold stimulus (i.e. stimulation over a greater area) would have been more likely to recruit 
DNIC.    
Investigations of conditioned pain modulation in man have employed a test stimulus which 
produces a subjective pain experience of magnitude 60 out of 100 using a numerical rating 
scale (Nirl et al. 2012), whilst effective conditioning stimuli have produced subjective pain 
experiences of magnitude 31.57 ± (SD) 9.56 out of 100 (moderate intensity) and 58.1 ± (SD) 
11.43 (severe intensity) (Nirl et al. 2012). It is possible that the electrical test stimulus used 
in this study was of a magnitude greater than the equivalent of 60 out of 100 in man, and 
generated a more robust nociceptive withdrawal response, suppression of which may have 
therefore been more difficult to induce. However, the stimulus chosen (5 x 5mA, 100Hz) 
produced a response approximating 50-60 % of maximum in our previous findings, 
therefore would have been expected to be of an appropriate magnitude to be applied as a 
test stimulus.   
 
The cold pressor test in man is reported to provoke 90-95% of the total reduction in skin 
temperature within the first minute (Wolf & Hardy 1941). Mourot et al. (2009) reported skin 
temperatures of 19 male subjects undergoing CPT, which were measured as 14.3 ± (SD) 
4.6oC and 13.4 ± (SD) 5.1oC following 2 and 3 minutes immersion respectively. We observed 
a much slower decline in skin temperatures, compared to studies of CPT in man, however 
the skin temperatures recorded in the present study reached similar temperatures to those 
reported by Mourot et al. (2009) at their nadir. Therefore, if skin temperature alone is the 
governing factor in the initiation of noxious cold related DNIC we would have expected to 
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see inhibition of the EMG responses at the 10 minute interval. Wolf & Hardy (1941) 
reported reduced pain in subjects that experienced slower cooling of the water bath, 
therefore it may be that the slow rate of change of skin temperature reflected a stimulus of 
insufficient magnitude to induce DNIC. Anatomical features identified in the footpads of 
dogs, including dermal arteriovenous anastomoses, a dermal venous plexus, and a thick 
layer of subcutaneous adipose tissue (Ninomiya et al. 2011) have been proposed to be 
adaptations to a cold environment. It is possible that, despite skin temperatures falling 
during immersion of the distal limb in ice water, these adaptations prevented tissue 
temperatures at the depth of cold nociceptors from falling to a degree necessary to 
represent a moderate or severe nociceptive stimulus. 
 
Both acepromazine (Alvaides et al., 2008) and alfaxalone (Rodríguez et al. 2012) exhibit 
vasodilator activity, which may have countered cold induced vasoconstriction, however 
administration of vasodilators by Wolf & Hardy (1941) did not alter the cold induced pain 
sensations in their subjects.  
 
Endogenous analgesia following the cold pressor test is reported to persist for at least 3-8 
minutes (Serrao et al. 2004), therefore, had we been able to induce DNIC, we would expect 
that test stimuli delivered at 5 minute intervals would be appropriate to demonstrate 
evidence of suppression of the NWR.  We did not deliver test stimuli more frequently, due 
to the concern that more frequent stimulations would result in sensitisation of the NWR. 
However, our work confirming the stability of responses to stimuli delivered at 60 second 




minutes, and therefore more frequent test stimuli could be employed in future DNIC 
studies, which would increase the sensitivity of the technique to short-lived effects.   
 
Acepromazine has central and peripheral antagonist activity at dopamine, α- adrenergic, 5-
hydroxytryptamine and histamine receptors, in addition to decreasing synaptic uptake of 
adenosine (Booth 1988), but is not considered to have analgesic or antinociceptive 
properties (Bergadano et al. 2009). Alfaxalone is reported to be devoid of analgesic activity 
(Winter et al. 2003), and its effects are mediated by potentiation of gamma-amino butyric 
acid (GABA) (Warne et al. 2015). DNIC is reportedly unaffected by GABA agonists (Kunz et al. 
2006); acepromazine sedation and alfaxalone sedation or anaesthesia would therefore be 
expected to provide suitable conditions for investigation of DNIC. However, there are no 
published studies describing the effects of different anaesthetics on CPM efficiency and 
testing characteristics, therefore, the possibility remains that sedation and anaesthesia 
could have modulated the expected responses. Reassuringly DNIC has been demonstrated 
in other species utilising a variety of anaesthetic agents to produce unconsciousness. In 
halothane anaesthetised rats DNIC has been successfully induced using noxious mechanical 
force at a number of body sites, noxious heat and electrical stimulation of the tail and 
intraperitoneal bradykinin (Le Bars et al. 1979), whilst in pentobarbitone anaesthetised 
rabbits cutaneous application of mustard oil to the snout has been used to induce DNIC 
(Harris 2016).  
In order to safeguard the welfare of animals exposed to a conditioning stimulus, the 
stimulus should be rapidly terminated, non-tissue damaging and rapidly effective, 
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permitting a short testing time. For these reasons, mechanical or ischaemic induced noxious 
conditioning stimuli were considered the most rewarding modalities to investigate further.  
These investigations into cold-water elicited DNIC in dogs were presented as a poster 






























































Electrical stability (late 
response) 
  
Temporal summation (early 
response) 
Temporal summation  
(late response) 
  Ln(µV.S) S.E. P Ln(mV.S) S.E. P Ln(mV.S) S.E. P Ln(mV.S) S.E. P Ln(mV.S) S.E. P Ln(mV.S) S.E. P Ln(mV.S) S.E. P 
Constant, recorded during 
ACP sedation (x=0) 
2.3773069 0.2941749 - -8.132 0.285 - -6.945 0.207 - -4.667 0.334 - -4.678 0.346 - -4.775 0.313 - -5.264 0.287 - 
Adjustment to constant by 
alfaxalone sedation 
0.0461343 0.3698821 0.901 -0.283 0.314 0.367 0.161 0.260 0.536 -1.427 0.489 0.004* -1.281 0.474 0.007* -2.528 0.441 <0.001* -1.504 0.442 <0.001* 
Adjustment to constant by 
alfaxalone anaesthesia 
-0.6934438 0.3928979 0.078 0.095 0.314 0.762 0.264 0.260 0.310 -1.491 0.512 0.004* -2.211 0.502 <0.001* -2.232 0.417 <0.001* -1.393 0.420 <0.001* 
Mechanical stimulus weight 0.0349592 0.0035281 <0.001* - - - - - - - - - - - - - - - - - - 
Mechanical stimulus weight2 -0.0002324 0.0000330 <0.001* - - - - - - - - - - - - - - - - - - 
Mechanical stimulus weight3 0.0000004 0.0000001 <0.001* - - - - - - - - - - - - - - - - - - 
Alfaxalone sedation x 
Stimulus weight 
-0.0343866 0.0051932 <0.001* - - - - - - - - - - - - - - - - - - 
Alfaxalone anaesthesia x 
Stimulus weight 
-0.0358420 0.0054657 <0.001* - - - - - - - - - - - - - - - - - - 
Alfaxalone sedation x 
Stimulus weight2 
0.0002368 0.0000486 <0.001* - - - - - - - - - - - - - - - - - - 
Alfaxalone anaesthesia  x 
Stimulus weight2 
0.0002451 0.0000511 <0.001* - - - - - - - - - - - - - - - - - - 
Alfaxalone sedation  x 
Stimulus weight3 
-0.0000005 0.0000001 <0.001* - - - - - - - - - - - - - - - - - - 
Alfaxalone anaesthesia  x 
Stimulus weight3 
-0.0000005 0.0000001 <0.001* - - - - - - - - - - - - - - - - - - 
Stimulus occasion - - - - - - - - - -0.078 0.064 0.223 - - - -0.268 0.062 <0.001* 0.235 0.056 <0.001* 
Stimulus occasion2 - - - - - - - - - 0.007 0.006 0.243 - - - 0.023 0.007 0.001* -0.015 0.006 0.012* 
Alfaxalone sedation  x 
Occasion 
- - - - - - - - - -0.062 0.096 0.518 - - - 0.195 0.093 0.036* -0.196 0.085 0.021* 
Alfaxalone anaesthesia x 
Occasion 





















Alfaxalone sedation  x 
Occasion2 
- - - - - - - - - 0.001 0.008 0.901 - - - -0.015 0.010 0.134 0.018 0.009 0.046* 
Alfaxalone anaesthesia x 
Occasion2 
- - - - - - - - - 0.025 0.009 0.005* - - - -0.027 0.010 <0.001* 0.007 0.009 0.437 
Stimulus current - - - 0.840 0.065 <0.001* 0.508 0.042 <0.001* - - - - - - - - - - - - 
Stimulus current2 - - - -0.050 0.006 <0.001* -0.027 0.004 <0.001* - - - - - - - - - - - - 
Alfaxalone sedation   x 
Current 
- - - -0.525 0.095 <0.001* -0.532 0.062 <0.001* - - - - - - - - - - - - 
Alfaxalone anaesthesia  x 
Current 
- - - -0.691 0.095 <0.001* -0.529 0.062 <0.001* - - - - - - - - - - - - 
Alfaxalone sedation  x 
Current2 
- - - 0.036 0.008 <0.001* 0.034 0.005 <0.001* - - - - - - - - - - - - 
Alfaxalone anaesthesia  x 
Current2 
- - - 0.052 0.008 <0.001* 0.035 0.005 <0.001* - - - - - - - - - - - - 
Table	S1	Effect sizes and P values of the predictor variables (and interactions between variables) included in the final models 		
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2.4.2 Paper 5. Hunt, J.R., Goff, M., Jenkins, H., Harris, J., Knowles, T.G., Lascelles, 
B.D.X., Enomoto, M., Mendl, M., Whay, H.R., Murrell, J.C., 2018. Electrophysiological 
characterisation of central sensitisation in canine spontaneous osteoarthritis. Pain 
159, 2318–2330. 
The development of EMG recording techniques suitable for use in anaesthetised dogs 
enabled the overarching project to proceed, with the aim of identifying electrophysiological 
changes in response to nociceptive stimuli in dogs affected by osteoarthritis, compared to 
an unaffected cohort. A prospective, non-blinded study was performed under the Animal 
(Scientific Procedures) Act 1986 (as amended, 2013) and the experimental protocol was 
approved by the University of Bristol Animal Welfare and Ethical Review Body. 
 
Client owned dogs with suspected pelvic limb osteoarthritis were recruited via advertising 
within the University of Bristol, surrounding veterinary clinics, and via a dedicated Facebook 
study page.  
Initially, we sought to recruit two groups of patients; those affected by OA (n = 100, 
anticipating that up to approximately 30% of these dogs may exhibit CS), and an age, breed, 
and sex matched control group (n = 35). However, during the recruitment phase it became 
apparent that a significant number of patients were currently being treated with NSAIDs. It 
was decided to recruit these animals without altering their daily NSAID treatment, but 
during data analysis these animals were identified as a separate group (OANSAID). We 
considered that this decision was justified given that pain and disability were still present in 




Interested dog owners were invited to an assessment visit where written and verbal 
descriptions of the projects aims and methods were provided. Owners who were willing to 
enroll their dog on the project were asked to sign a consent form but advised that they 
could withdraw at any time. I performed a clinical and musculoskeletal examination of all 
enrolled dogs, to rule out any non-orthopaedic causes of pelvic limb pain or stiffness. 
Jugular blood samples were obtained and submitted for biochemical and haematological 
testing in order to exclude diseases which may impact general anaesthesia. Owners were 
asked to complete clinical metrology instruments, considering their dog’s health over the 
previous seven days.  
Dogs which continued within the study then underwent alfaxalone total intravenous 
anaesthesia (based on the investigations described in paper 4), following acepromazine 
premedication. Under alfaxalone anaesthesia, radiography of elbow, stifle, coxofemoral, 
and lumbosacral joints was performed. Following radiography, EMG recording at the cranial 
tibial muscle was performed to evaluate nociceptive threshold, stimulus-response 
characteristics, and temporal summation to dermal electrical stimulation of the plantar 
aspect of the third digit. I remained unaware of the results of the radiographic imaging 
during the EMG testing procedure.  
Given the disappointing results related to evoking DNIC using a cold water stimulus, we 
undertook a further review of the literature relating to conditioned pain modulation in 
humans. It was considered that injection of substances such as capsaicin or hypertonic 
saline may result in pain which continued beyond the duration of anaesthesia, and that this 
would be inappropriate in client owned animals. A mechanical stimulus offered the 
advantage of being rapidly terminated, and preliminary experiments were performed using 
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application of a bulldog clip to my fingers in order to ascertain that the stimulus was painful 
but tolerable, and that it did not result in any tissue damage when applied for a duration in 
excess of one minute. A subset of 11 OA and 12 control dogs underwent DNIC evaluation 
using the mechanical stimulus. A baseline EMG response was established by delivering 
electrical stimuli at twice the individually determined nociceptive threshold at a rate of 1Hz 
for 100 seconds. This was repeated three more times at five minute intervals, during the 
second and third sessions the bulldog clip was applied to the third digit of the thoracic limb 
contralateral to EMG recording for a duration of 20 seconds.  
 
As in the previous paper, the hierarchical structure of the data relating to repeated NWR 
stimulations was accounted for by using multilevel general linear modelling, enabling 
exploration of factors such as age and bodyweight on the experimental data.  
 
Analysis of owner completed metrology instruments, veterinary musculoskeletal 
assessments and radiographic OA scores demonstrated significant differences between 
groups, supporting the criteria for group allocation. Significant group level differences in the 
processing of nociceptive stimuli were identified; animals affected by OA exhibited larger 
increases in EMG responses to increasing levels of nociceptive stimulation, regardless of 
NSAID treatment, indicating that OA affected dogs experienced augmented processing of 
nociceptive signaling, consistent with central sensitisation. A seemingly paradoxical increase 
in electrical nociceptive threshold was identified in OA dogs compared with the control 
group, although neither group exhibited different thresholds to OANSAID. However, the 




especially in light of the data from QST research (Sanchis-Mora et al. 2017), it is possible 
that this finding related to age rather than disease status.   
Although small numbers of animals underwent DNIC testing using a mechanical conditioning 
stimulus, EMG data demonstrated that this conditioning stimulus did evoke endogenous 
anti-nociception in control animals, and that this was impaired in dogs affected by OA, 
suggesting that this is one of the mechanisms likely to contribute to the state of central 
sensitisation in dogs suffering from OA. A potential therapeutic strategy aimed at restoring 
endogenous nociceptive modulation (Bannister et al., 2015) may therefore have merit in the 
treatment of canine OA in some cases. Data from the study were presented in two abstracts 
at the Association of Veterinary Anesthetists Spring Meeting in March 2017. Since the 
publication of paper 5, three papers investigating CPM in conscious dogs have been 
published. In the first Ruel et al., (2018) evaluated the effects on mechanical nociceptive 
threshold of a ischaemic pain, produced by inflation of a blood pressure cuff to supra-
systolic pressure, in healthy dogs. In this study dogs, in which testing was deemed clearly 
feasible, demonstrated an increase in mechanical nociceptive threshold associated with the 
conditioning stimulus. This effect was not observed in dogs in which feasibility of testing 
was judged less than ideal. Monteiro et al., (2018), also evaluated CPM by measuring 
changes in mechanical nociceptive threshold associated with ischaemic pain caused by a 
blood pressure cuff. In this study 13 dogs affected by appendicular osteosarcoma (OSA) 
demonstrated less efficacious CPM compared to seven healthy controls, however no age 
matching of groups was attempted. All of the control dogs were less than 3 years of age, 
whilst the OSA group had a mean age of approximately 7 and a half years. In man 
decreasing CPM efficacy is associated with increasing age (Grashorn et al., 2013), however 
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once the OSA dogs were treated with cimicoxib their CPM normalised, suggesting that the 
disease, rather than age was responsible for the initial group differences. Chiu et al., (2020) 
evaluated CPM by measuring changes in thermal and mechanical threshold associated with 
heterotopic mechanical nociceptive stimulation in 11 dogs affected by OA, compared with 
13 healthy controls. Compared with the control group, the OA group were significantly 
older. However, the logistic regression model indicated that OA status was a significant 
predictor of CPM efficacy, whilst age was not significant in the model. The potential benefits 
of assessing CPM in conscious dogs are that it may be more readily performed in clinical 
environments and obviates the need for anaesthesia. Potential drawbacks include ethical 
concerns over inducing pain of sufficient magnitude to elicit CPM, feasibility, and potential 
cortical modulation of both nociceptive threshold (stress induced analgesia; anxiety induced 
hyperalgesia (Rhudy & Meagher, 2000) and behavioural responses, which may confound 






























2.5 General discussion 
We identified that buprenorphine was the most widely available opioid in paper 2, 
consistent with the findings of other authors (Brodbelt, 2006), however the evidence from 
paper 1 suggested that methadone represented a more efficacious analgesic in dogs 
undergoing orthopaedic surgery. This finding could potentially represent suboptimal 
management of perioperative pain and therefore, based on the methods developed in 
Paper 1, we have undertaken further work comparing the efficacy of methadone with 
buprenorphine in dogs and cats undergoing ovariohysterectomy (Shah et al., 2018b; Shah et 
al., 2018a). This work also suggested that methadone demonstrates greater efficacy 
compared with buprenorphine in both of these surgeries, with the caveat that NSAIDs were 
administered at the conclusion of the assessment period, in contrast to the study design 
used in Paper 1. The finding of superior efficacy of the authorised dose of methadone 
compared to that of buprenorphine was important to disseminate to first opinion veterinary 
surgeons and was communicated by the head of the Bristol Anaesthesia and Analgesia 
Research Group, Dr. Jo Murrell, during a series of lectures delivered for Dechra5. Further 
surveys on prescribing practice of veterinary surgeons would be hoped to demonstrate an 
increasing prescription of methadone for perioperative analgesia. A question remains as to 
the the most appropriate statistical handling of Short Form Glasgow Composite Pain Scale 
data in longitudinal research studies, where animals are unable to walk owing to excessive 
sedation at some time points. A comparison of agreement between the two different 
                                                        
5 https://www.dechra.co.uk/news/archive-news/pain-management-cpd-sessions-hailed-a-




suggested methods for completing the GCPS-SF (converting to a decimel or scoring a 
maximum for all dogs that are too sedated to stand) with a contemporaneously assessed 
DIVAS may yield further information on the relative merits of each approach.  
The increase in prescription of perioperative analgesics provides benefits in terms of 
improved pain management, but increases the number of animals exposed to drugs and 
potentially at risk for associated adverse events. The limitations of current passive adverse 
event reporting in animals are discussed in paper 3 and it is to be hoped that whilst we were 
unable to provide reliable estimates for the incidence of adverse events related to NSAID 
treatment, the paper raised awareness of the knowledge gaps in this area. Whilst we were 
able to quantify the frequency of NSAID associated AEs that were reported to the VMD 
there remains an urgent need for more accurate evidence regarding the incidence and 
severity of NSAID associated AEs (Belshaw et al., 2016). A better estimation of the incidence 
of AEs across a representative population might be achievable through data collation 
initiatives such as VetCompass™, though there are currently no projects listed on the 
VetCompass™ webpages with this aim6. Whilst NSAIDs are reportedly effective in managing 
canine osteoarthritis pain (Sanderson et al., 2009), the cohort of dogs treated with NSAIDs 
in paper 5 continued to show evidence of augmented nociceptive processing. The 
electrophysiological demonstration of central sensitisation associated with osteoarthritis, 
despite NSAID treatment, provides the basis to investigate the effects of centrally acting 
analgesics and anti-hyperalgesics on spinal nociceptive processing. Additionally our 
described technique to elicit DNIC in anaesthetised dogs obviates the clear ethical and 
                                                        
6 https://www.rvc.ac.uk/vetcompass/projects?filter=15703,15724 accessed February 16, 2020. 
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welfare concerns of delivering moderately painful stimuli over a period of time to a 
conscious animal that is unable to appreciate the reason for the application of the stimulus. 
Given the findings of normalisation of CPM in conscious dogs treated with cimicoxib 
(Monteiro et al., 2018) it would be informative to evaluate the effect of this drug on DNIC 




3. Contributions to Other Research and Communication of Research 
Findings. 
The expertise that I developed during the clinical research on acute pain meant that I was 
invited to contribute to the design and manuscript writing of the research project “A non-
inferiority trial comparing paracetamol / codeine and meloxicam for post-operative 
analgesia in dogs”, which has recently been accepted for publication (Pacheco et al. 2020). 
Data relating to physiological measures recorded during alfaxalone total intravenous 
anaesthesia in dogs (Paper 5) have been published, increasing the evidence base for the use 
of this technique clinically in middle aged to older dogs (Hunt et al., 2019a).  
During the BBSRC research project I was able to act as MSc co-supervisor for Megan Goff, 
and we collaborated on the research project “Docosahexaenoic acid for the treatment of 
joint pain in dogs with osteoarthritis: A randomised, double-blinded, placebo-controlled 
trial”, which has been submitted for publication to The Veterinary Journal. During my work 
in the field of analgesia I have been invited to produce articles on pain assessment and 




review articles on the current state of knowledge regarding QST in dogs (Hunt et al., 2019b), 
and co-author the chapter on chronic and osteoarthritic pain in the BSAVA Guide to Pain 
Management in Small Animal Practice (White & Hunt, 2019). I was invited to deliver a 
lecture “An update on opioids”, and join fellow speakers Samantha Lindley and Louise Clark 
in a panel presentation of pain management cases at the Association of Veterinary 
Anaesthetists residents day in March 2017. 
 
4. Future Research. 
I am currently working full time in clinical practice and am committed to continuing to 
remaining involved in research in companion animal pain management. Ethical review has 
been granted by the RCVS for a prospective, randomised, placebo controlled trial of 
palmitoylethanolamide for adjunctive analgesia in dogs undergoing hemilaminectomy, 
employing validated pain scales and mechanical nociceptive threshold testing, together with 
total opioid consumption as outcome measures. Data collection was planned to begin in 
early 2020, but is currently delayed by changes in working patterns resulting from 
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